Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2764-2770

  Gozalbes, R ^a   Brun Pascaud, M ^a   Garcia Domenech, R ^a   Galvez, J ^a   Girard, P M ^a   Doucet, J P ^a   Derouin, F ^a  

^a Laboratoire d'Excellence Inflamex   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; ENOXACIN; FLEROXACIN; FLUMEQUINE; GATIFLOXACIN; GREPAFLOXACIN; IRLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PD 115311; PD 138362; PD 139586; PEFLOXACIN; PIPEMIDIC ACID; PIROMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROSOXACIN; RUFLOXACIN; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; ANALYTIC METHOD; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG POTENCY; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; STATISTICAL MODEL; VALIDATION PROCESS; VIRTUAL REALITY;

ANTI-INFECTIVE AGENTS, QUINOLONE; COMPUTER SIMULATION; MODELS, BIOLOGICAL; MYCOBACTERIUM AVIUM COMPLEX; PREDICTIVE VALUE OF TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T;

EID: 0033802513     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2764-2770.2000     Document Type: Article

References (30)

1. Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii and Mycobacterium avium complex infections in a rat model
2. Fluoroquinolones: Mechanisms of action and resistance
3. Classification and structure-activity relationships of fluroquinolones
4. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium
5. Virtual Combinatorial Syntheses and Computational Screening of new potential anti-Herpes compounds
6. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
7. Pharmacological distribution diagrams: A tool for de novo drug design
8. Topological approach to drug design
9. Charge indexes. New topological descriptors
10. Molecular search of new active drugs against Toxoplasma gondii
11. Discovery of new antimalarial compounds by use of molecular connectivity techniques
12. Prediction of chromatographic properties of organo-phosphorus insecticides by molecular connectivity
13. Stepwise discriminant analysis
14. In vitro activity of ciprofloxacin and ofloxacin against the M. avium-intracellulare complex
15. An electrotopological-state index for atoms in molecules
16. New approaches and technologies in drug design and discovery
17. N-1-tert-Butyl-substituted quinolones: In vitro anti-Mycobacterium avium activities and structure-activity relationship studies
18. In vitro anti-Mycobacterium avium activities of quinolones: Predicted active structures and mechanistic considerations
19. Anti-Mycobacterium avium activity of quinolones: In vitro activities
20. Anti-Mycobacterium avium activity of quinolones: Structure-activity relationship studies
21. Virtual combinatorial chemistry
22. Mycobacteria and the new quinolones
23. Some comments on Cp
24. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages
25. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome
26. Mycobacterial infections and AIDS patients, with an emphasis on the Mycobacterium avium complex
27. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria